We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 1,301

GSK responding to inquiries from SFO, DOJ, and SEC regarding its use of third party advisors in China
  • Buckley Sandler LLP
  • USA
  • February 9 2018

In a securities filing on Wednesday, Feb. 7, U.K.-based pharmaceutical company GlaxoSmithKline PLC (“GSK”) announced that it is responding to

Medicare Part D Cost Sharing Trends for Adult Vaccines
  • Manatt Phelps & Phillips LLP
  • USA
  • January 30 2018

Vaccination utilization among U.S. adults is low, and well below the Healthy People 2020 targets, despite widespread availability of safe and

English Court extends funder’s liability for security for costs beyond funding commitment
  • Jenner & Block LLP
  • United Kingdom
  • January 25 2018

The recent decision in Sandra Bailey & Others v GlaxoSmithKline UK Ltd represents an important development in the law concerning the liability of

More headaches for Reckitt Benckiser as GSK wins misleading comparative advertising dispute
  • Davies Collison Cave
  • Australia
  • January 22 2018

Justice Foster of the Federal Court has held that Reckitt Benckiser (Reckitt) lacked an adequate foundation in scientific knowledge to make certain

GSK and Novartis are in hot water for mislabelling Voltaren Osteo Gel to charge price premium
  • Cordato Partners
  • Australia
  • December 14 2017

Fresh from its success in the Nurofen Specific Pain products proceedings, the Australian Competition & Consumer Commission (ACCC) is looking for a

Post-Grant Proceedings as a Freedom-To-Operate Tool
  • Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • USA
  • October 30 2017

While some may take it as a given that patent owners view America Invents Act post-grant proceedingsinter partes reviews and post-grant

How Companies Should Prep for Enforcement Shift to State AGs
  • Foley & Lardner LLP
  • USA
  • August 23 2017

“Top Cop” is how every state Attorney General wants to be known. In reality, state AGs have far more authority for civil enforcement than they do for

GlaxoSmithKline Consumer Healthcare (UK) IP Limited 2017 NZIPOTM 6 (2 March 2017)
  • Spruson & Ferguson
  • Australia
  • August 3 2017

This matter concerned a notice of intention to reject the following series of mark: The application is owned by GlaxoSmithKline Consumer Healthcare

SCOTUS Ruling Gives a Boost to Biosimilars; FDA Continues to Advance Products Through AdComs
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • June 14 2017

On a sweltering hot D.C. morning, those of us anxiously awaiting the Supreme Court’s opinion in its first case involving biosimilar biological

Liability as joint tortfeasor & the statute of limitation
  • Stobbs IP
  • United Kingdom
  • May 24 2017

Regular readers of our blog will already be familiar with the ongoing trade mark infringement and counterclaim battle between Glaxo and Sandoz, see